Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÁøÇàµÈ µÎ°æºÎ¾ÏÀÇ È­Çпë¹ý

Chemotherapy in advanced head and neck cancer

±¸°­»ý¹°Çבּ¸ 1986³â 9±Ç 1È£ p.85 ~ 93
±èÇпø, ÇѼºÀÏ, Ȳ°æ°ï,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÇпø ( Kim Hak-Won ) - Á¶¼±´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­¾Ç¾È¸é¿Ü°úÇб³½Ç
ÇѼºÀÏ ( Han Sung-Il ) - Á¶¼±´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­¾Ç¾È¸é¿Ü°úÇб³½Ç
Ȳ°æ°ï ( Hwang Kyung-Kon ) - Á¶¼±´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­¾Ç¾È¸é¿Ü°úÇб³½Ç

Abstract


Adjuvant chemotherapy using combination of several affective agents has very striking anti-tumor activity. Moreover full doses of radiotherapy can be delivered following such combined chemotherapy without any unanticipated side effects or increased radiation sensitivity of normal tissues. Surgery following combined chemotherapy dose not result in increased wound healing complicaions, and it dose not limit the spectrum of reconstructive techniques currently usable for surgical rehabilitation.
But combined chemotheapy dose not seem to decrease distant metastases. The role of this type of chemotherapy in producing increased survival is unknown at the present time.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI